EGFR and breast cancer: The activation of HER2-3 and EGFR by the neurotensin/neurotensin receptor 1 system renders breast tumors aggressive, and the administration of neurotensin receptor 1 antagonists blocked the adherence and migration/invasion of BC cells [216].